Visoluten®
Biologically active food supplement VISOLUTEN® contains a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, isolated from the tissues of the eyes of young animals -
calves up to 12 months of age or pigs.
VISOLUTEN® is available in capsules with an active substance content of 10 mg.
VISOLUTEN® peptides regulate metabolic processes in the cells of the eye tissues, increase the reserve
capabilities of the organ of vision, have a beneficial effect on the adaptation processes of the body
in extreme conditions, have antioxidant properties, and regulate the processes of peroxidation in the
tissues of the eye. Experimental studies have shown that peptides have a tissue-specific effect on
the cells of those tissues from which they are isolated. This allows us to assume the effectiveness of
the use of VISOLUTEN® for the restoration of visual functions in case of disorders of various origins.
According to experimental data, VISOLUTEN® promotes the normalization of functional and
morphological disorders of the organ of vision.
The development of treatment tools that allow for the complete rehabilitation of patients with eye
injuries and their consequences, dystrophic diseases of various eyeball structures is an urgent and
complex problem in ophthalmology. Hereditary or post-traumatic insufficient vitality of eye tissues
often leads to their progressive destruction (1, 2).
Drug treatment of these diseases includes the use of the following drugs (1, 3):
- Vitayodurol, vitafacol;
- Vitamins B1, B6;
- Biostimulants (aloe, FiBS);
- etc.
The clinical study of VISOLUTEN® was carried out at the Medical Center of the St. Petersburg Institute
of Bioregulation and Gerontology from January to August 2011.
A clinical trial of VISOLUTEN® was carried out in patients with dystrophic diseases of the retina of
the eye of various etiologies and post-traumatic endothelial-epithelial corneal dystrophies. The study
involved 49 patients randomly divided into 2 groups - the control group (20 people) and the primary
group (29 patients). The distribution of patients by groups is shown in Table 1.
Patients in the control group received conventional therapy. In addition to conventional treatment,
patients of the primary group were prescribed VISOLUTEN® orally 10-15 minutes before meals, 1-3
capsules 2-3 times a day for 30 days, depending on the severity of the pathological process. For post-
traumatic visual impairments, VISOLUTEN® was prescribed in the rehabilitation period after surgery.
A progressive narrowing of the visual fields decreased visual acuity, degenerative changes in the retina
and narrowing of the retinal vessels were registered when examining patients.
Distribution of patients by diagnosis, sex and age. Table 1
Diagnosis Age Group Male Female Total
Retinal dystrophic diseases 51-70 Control 4 6 10
Primary 8 9 17
Posttraumatic endothelial-epithelial 20-43 Control 5 5 10
corneal dystrophies
Primary 7 5 12
Total: 24 25 49
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.